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Abstract
It has been hypothesized that the association between hypertension and gout is bidirec-
tional, however, few studies have examined this in a prospective cohort. We analyzed
data from the Singapore Chinese Health Study (SCHS) follow-up I (1999–2004) and II
(2006–2010) interviews, when both physician-diagnosed hypertension and gout were
self-reported. We included participants with data for both follow-up interviews and who
were free of heart disease, stroke and cancer at follow-up I. The analysis of hypertension
and risk of gout included 31,137 participants when prevalent gout cases were excluded,
while the analysis of gout and risk of hypertension included 20,369 participants when
prevalent hypertension cases were excluded. Cox proportional hazards models were
used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals
(CIs). The mean age at follow-up I was 60.1 (SD 7.3) years, and the average follow-up
was 6.8 (SD 1.4) years. In the analysis of hypertension and risk of gout, 682 incident
cases were identified. Compared to normotensive participants, hypertensive patients had
an88% increased risk of developing gout (HR 1.88; 95% CI 1.61–2.21). In the parallel
analysis, 5,450 participants reported to have newly diagnosed hypertension during follow-
up. Compared to participants without gout, those with gout had an18% increased risk of
developing hypertension (HR 1.18; 95% CI 1.02–1.37). The bidirectional association was
stronger in normal weight adults compared to overweight/obese individuals (Pinteraction =
0.06 and 0.04, respectively). The hypertension to gout association was stronger in women
compared to men (Pinteraction = 0.04), while the gout to hypertension association was evi-
dent in women but not in men (Pinteraction = 0.02). In conclusion, our results suggest that
the hypertension-gout association is bidirectional in this cohort of Singapore Chinese
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adults. The potential interactions of the bidirectional association with obesity and sex
deserve further investigations.
Introduction
Hypertension is a leading risk factor for global disease burden, contributing to 7.0% of global
disability-adjusted life years [1]. Hypertension is highly prevalent in both developed countries
(e.g., about 30% in US adults) [2] and developing countries (e.g., about 30% in Chinese adults)
[3]. Meanwhile, gout is a common arthritis caused by deposition of monosodium urate crystals
within joints due to hyperuricaemia [4], and is more common in men and elderly populations
[5,6]. The prevalence of gout varies dramatically in different populations due to the differences
in diagnosis criteria, study population and study design [7]. Studies in US adults have reported
a prevalence of self-reported gout to be 4.6% in men and 2.0% in women aged>45 years [8],
and a Taiwan survey reported 8.2% in men and 2.3% in women in 2005–2008 [9].
Both hypertension and gout are associated with increased risk of cardiovascular disease
morbidity and mortality [10–15]. Therefore, an association between hypertension and gout in
middle-aged and elderly individuals deserves careful examination. It has been observed in dif-
ferent populations that hypertension is positively associated with both prevalent and incident
gout [16]. Meanwhile, growing evidence has also linked hyperuricaemia with the development
of incident hypertension [17]. Although it has been hypothesized that the hypertension-gout
relation is bidirectional, few studies have addressed this hypothesis in a prospective setting,
particularly in the Asian populations. Therefore, in this study, we aimed to examine the bidi-
rectional association between hypertension and gout in a prospective cohort of middle-aged
and older Chinese in Singapore.
Methods
Study population
We used data from the Singapore Chinese Health Study (SCHS), a population-based cohort of
63,257 Chinese adults aged 45–74 years at enrolment (1993–1998) [18]. The participants were
recruited from two major Chinese dialect groups in Singapore, the Hokkien and Cantonese.
Trained interviewers conducted the face-to-face interviews in participants’ homes at recruit-
ment, and obtained the information on demographics, height, weight, tobacco use, physical
activity, dietary habits and medical history. Two follow-up interviews were conducted via tele-
phone among surviving participants between 1999 and 2004, and again between 2006 and
2010 to update information on selected lifestyle factors and medical history. The study was
approved by the institutional review board of the National University of Singapore, and all par-
ticipants gave written informed consents.
We used the follow-up I interview (1999–2004) as baseline for our analysis because both
gout and hypertension were enquired at this time among 52,322 surviving participants who
participated in this interview. During the follow-up II interview (2006–2010), 39,528 partici-
pants were re-contacted and information on gout and hypertension was updated.
Assessment of hypertension and gout
Specifically, at both follow-up interviews, the participants were asked separately if they had
been told by doctors that they had hypertension or gout. If the response was “yes”, participants
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were also asked about the age of first diagnosis. For cases of gout, the interviewers confirmed
that the participants had gout but not other arthritis by verifying with the participants that the
diagnosis was based on joint pain and swelling attributed to reported hyperuricemia by their
physicians. All interviews were tape-recorded and subjected to quality checks.
Assessment of covariates
At recruitment (1993–1998), participants were asked about their education level, height,
weight, tobacco use, physical activity, alcohol intake and medical history. At follow-up I inter-
view (1999–2004), information on body weight, smoking status, alcohol intake and medical
history was further updated. Body mass index (BMI) was calculated by weight in kg divided by
square of height in meters.
Statistical analysis
A total of 37,509 individuals participated in both follow-up interviews with complete informa-
tion on hypertension and gout. We excluded 4,836 participants with history of cancer, coro-
nary heart disease or stroke at follow-up I interview, leaving 32,673 participants for analysis.
For the relation of hypertension with incident gout (analysis 1), individuals with history of
gout (n = 1,536) were further excluded and the final analysis included 31,137 participants. For
the analysis of gout and incident hypertension (analysis 2), individuals with prevalent hyper-
tension (n = 12,304) were further excluded and the final analysis included 20,369 participants.
The study flow is shown in Fig 1.
For both analyses, we first compared means or proportions of covariates according to base-
line status of hypertension (analysis 1) and gout (analysis 2) at follow-up I interview. For these
comparisons, we used χ2 tests for categorical variables and t-test for continuous variables. Per-
son-years for each participant were calculated from date of follow-up I interview to the date of
reported outcome diagnosis (gout in analysis 1 and hypertension in analysis 2), or the follow-
up II interview, whichever occurred first. Cox proportional hazards regression was used to cal-
culate hazard ratio (HR) and its 95% confidence interval (CI), with adjustment for age (years),
sex, dialect (Hokkien/Cantonese), year of follow-up I interview (1999–2001, 2002–2004), edu-
cational level (none, primary school, secondary school or higher), moderate physical activity
level (<0.5, 0.5–3.9,4.0 hours/week), smoking status (never, former, current), alcohol con-
sumption (none, monthly, weekly, daily), BMI (<20.0, 20.0–23.9, 24.0–27.9,28.0 kg/m2),
and self-reported history of diabetes.
Previous studies have suggested substantial sex differences in prevalence of gout [5.6], and
potential sex differences in the relation between hyperuricemia and hypertension [17], thus, we
also stratified our analyses by sex. Potential interaction tests were explored with categories for
age (<60 and60 years), BMI (<24.0 and240 kg/m2), and smoking (never and ever smok-
ers). We also conducted a 2-year lag sensitivity analysis after excluding early-onset cases. All
reported P values were 2-sided, and statistical analysis was performed with SAS version 9.2
(SAS Institute, Cary, North Carolina, USA).
Results
The characteristics of the participants at follow-up I interview are shown in Table 1. Compared
to normotensive participants, hypertensive patients were older, had higher BMIs and more
likely to be current smokers and have diabetes. The differences of other characteristics were
small but statistically significant, probably because of large sample size. Compared to individu-
als without gout, participants with gout at follow-up I visits were younger, had higher BMIs,
more likely to be male and former smokers, and to have higher education levels.
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Hypertension and risk of incident gout (analysis 1)
After a mean follow-up of 6.9 (SD 1.3) years, 682 participants reported to have incident gout.
Hypertension was associated with an 88% increased risk of developing gout (HR 1.88; 95% CI
1.61–2.21; Table 2). A dose-response relation was observed between duration of hypertension
and gout (Ptrend<0.001). The association was not materially changed in the 2-year lag analysis
(HR 1.85; 95% CI 1.57–2.18).
We found significant interactions with sex and BMI, but not other variables. The association
was slightly stronger in women (HR 2.08; 95% CI 1.66–2.60) compared to men (1.67; 1.33–
2.09; Pinteraction = 0.04; Table 2); marginally stronger in normal weight adults (BMI<24 kg/m
2;
2.11; 1.69–2.64) compared to overweight/obese individuals (BMI24 kg/m2; 1.66; 1.33–2.07;
Pinteraction = 0.06).
Gout and risk of incident hypertension (analysis 2)
In the parallel analysis of gout and risk of hypertension, 5,450 participants reported to have
new-onset hypertension during a mean follow-up of 6.2 (SD 1.9) years. Compared to partici-
pants without gout, those with gout had an 18% increased risk of developing hypertension (HR
1.18; 95% CI 1.02–1.37; Table 3). A dose-response association between duration of gout and
risk of hypertension was observed (Ptrend = 0.03; Table 3). The association was not substantially
different in the 2-year lag analysis (1.16; 0.99–1.35).
We found significant interactions with sex and BMI, but not other variables. The association
was evident in men (HR 1.31; 95% CI 1.09–1.58) but not in women (0.93; 0.72–1.19; Pinteraction
= 0.02; Table 3); present in normal weight adults (1.34; 1.09–1.65) but not among overweight/
obese individuals (1.01; 0.81–1.25; Pinteraction = 0.04).
Fig 1. Study flow.
doi:10.1371/journal.pone.0141749.g001
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Discussion
The present study, from a large cohort of middle-aged and elderly Chinese in Singapore, is the
first prospective study to examine the bidirectional association between hypertension and gout,
and adds to the growing evidence that they are closely related to each other. Overall, hyperten-
sion was associated with an 88% increased risk of developing gout, while gout was related to an
18% increased risk of incident hypertension. This reciprocal association also depends on sex
and baseline obesity status. All the associations were independent of socio-demographic vari-
ables and lifestyle factors.
Hypertension is a common comorbidity in patients with gout. It has been estimated that
74% of the gout patients had hypertension in a national survey among US general population
[19]. This phenomenon has been observed in other studies as well [20,21], including a large
study in Chinese population in Hong Kong [22]. However, the comorbidity of gout and hyper-
tension could be explained by the scenario that gout may be a consequence of having hyperten-
sion or as a risk factor for the onset of hypertension. Therefore, the temporal association
between the two conditions has attracted a lot of attention in the past several decades [23].
Table 1. Characteristics of cohort participants at follow-up I interview (1999–2004) in the two analyses: The Singapore Chinese Health Study.
Characteristics Analysis 1: hypertension to incident gout Analysis 2: gout to incident hypertension
Baseline hypertensive
patients
Participants without
hypertension
P
valuea
Participants with
baseline gout
Participants
without gout
P
valuea
Number of participants 11397 (36.6) 19740 (63.4) 573 (2.8) 19796 (97.2)
Age, y 61.3 ± 7.3 59.3 ± 7.2 <0.001 58.5 ± 6.6 59.3 ± 7.2 0.005
Body mass index, kg/
m2
24.1 ± 3.5 22.5 ± 3.3 <0.001 23.9 ± 3.2 22.5 ± 3.3 <0.001
Male 4403 (40.7) 7982 (40.4) <0.001 346 (60.4) 8010 (40.5) <0.001
Cantonese Dialect 5748 (50.4) 9712 (49.2) 0.04 279 (48.7) 9746 (49.2) 0.80
Diabetes 2393 (21.0) 1456 (7.4) <0.001 48 (8.4) 1460 (7.4) 0.37
Education level <0.001 <0.001
No 3014 (26.5) 4319 (21.9) 65 (11.3) 4326 (21.9)
Primary school 5119 (44.9) 8855 (44.9) 236 (41.2) 8880 (44.9)
Secondary school or
higher
3264 (28.6) 6566 (33.3) 272 (47.5) 6590 (33.3)
Smoking status <0.001 <0.001
Never 8612 (75.6) 14082 (71.3) 365 (63.7) 14120 (71.3)
Former 1630 (14.3) 2241 (11.4) 108 (18.9) 2248 (11.4)
Current 1155 (10.1) 3417 (17.3) 100 (17.5) 3428 (17.3)
Physical activity <0.001 0.055
<0.5 hours/week 8768 (76.9) 15604 (79.1) 430 (75.0) 15647 (79.0)
0.5–3.9 hours/week 1674 (14.7) 2735 (13.9) 91 (15.9) 2742 (13.9)
4 hours/week 955 (8.4) 1401 (7.1) 52 (9.1) 1407 (7.1)
Alcohol intake <0.001 0.01
Abstainers 10381 (91.1) 17400 (88.2) 482 (84.1) 17448 (88.1)
Weekly drinkers 743 (6.5) 1743 (8.8) 69 (12.0) 1750 (8.8)
Daily drinkers 273 (2.4) 597 (3.0) 22 (3.8) 598 (3.0)
Values are shown in mean ± standard deviation or n (%).
aP value was calculated by t-test for continuous variables and χ2 test for categorical variables.
doi:10.1371/journal.pone.0141749.t001
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Population-based prospective studies have consistently shown a positive relation between
hypertension and risk of developing gout [24–31]. For example, in an early analysis of a
12-year follow-up study from the Health Professional Follow-up Study, Choi et al. [27] found
that the multivariable relative risk (RR) was 2.31 (95% CI 1.96–2.72), and this association was
independent of diuretic use. In the Atherosclerosis Risk in Communities Study, McAdams-
DeMarco et al. [30] found a 2-fold risk of developing gout in hypertensive patients (RR 2.00;
95% CI 1.54–2.61) during 9 years of follow-up, and the association was substantially attenuated
after adjustment for serum urate levels. A recent cohort study in Chinese population in Taiwan
found a 32%-34% higher risk of gout among hypertensive men and women [31]. Therefore,
our findings are broadly consistent with the current literature and demonstrate that hyperten-
sion is an independent risk factor for gout development. In our study, we confirmed that the
Table 2. Hazard ratios (95% confidence intervals) for risk of gout according to hypertension status:
The Singapore Chinese Health Study (1999–2010).
Cases/person-years Model 1 Model 2
Baseline (follow-up I) hypertension status
No 318/136380 1.00 (ref) 1.00 (ref)
Yes 364/77861 2.06 (1.77–2.40) 1.88 (1.61–2.21)
Stratiﬁed by sexa
Men
No 171/54448 1.00 (ref) 1.00 (ref)
Yes 163/29671 1.75 (1.41–2.17) 1.67 (1.33–2.09)
Women
No 147/81932 1.00 (ref) 1.00 (ref)
Yes 201/48190 2.39 (1.93–2.97) 2.08 (1.66–2.60)
Stratiﬁed by BMI categorya
Normal weight
No 180/97749 1.00 (ref) 1.00 (ref)
Yes 160/41705 2.11 (1.70–2.62) 2.11 (1.69–2.64)
Overweight/obesity
No 138/38631 1.00 (ref) 1.00 (ref)
Yes 204/36156 1.62 (1.30–2.01) 1.66 (1.33–2.07)
Duration of hypertension
No hypertension 318/136380 1.00 (ref) 1.00 (ref)
0.1–4.9 years 89/25992 1.50 (1.18–1.89) 1.38 (1.09–1.76)
5.0–9.9 years 107/19753 2.39 (1.92–2.98) 2.21 (1.77–2.77)
10.0 years 146/24666 2.67 (2.18–3.26) 2.44 (1.98–3.01)
P for trendb <0.001 <0.001
2-year lag analysisc
No 300/96918 1.00 (ref) 1.00 (ref)
Yes 337/55094 2.02 (1.73–2.36) 1.85 (1.57–2.18)
Model 1: adjusted for age, sex, dialect, year of interview, and educational level.
Model 2: model 1 plus body mass index, physical activity, smoking status, alcohol use, and history of
diabetes at follow-up I.
aThe P for interaction was 0.04 for sex, and 0.06 for BMI category (<24 and 24 kg/m2).
bP for trend was calculated by treating the categorical variable of duration of hypertension as a continuous
variable.
c45 participants were excluded from the analysis.
doi:10.1371/journal.pone.0141749.t002
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incidence rate standardized to the age structure of the whole cohort was higher in men (3.9 per
1000 person-years) compared to that in women (2.7 per 1000 person-years), which is consis-
tent with the literature that gout is more common in men [5,6]. Interestingly, we found that
the relation was slightly stronger in women, which is consistent with a cohort study conducted
in a UK general practice database [29]. The Framingham Heart Study also found a slightly
stronger association in women compared to that in men, although the interaction was not sta-
tistically significant [28], while some other studies did not find the effect modification by sex
[30,31]. Thus, whether the association is different in men and women remains unclear. The rel-
atively stronger association in normal weight participants compared to that in overweight/
obese individuals suggests that hypertension confers greater risk for gout in lean people. How-
ever, a previous study in US population did not found significant interaction with obesity status
[30]. The stronger associations in women and normal weight individuals also suggest that the
effect of hypertension on risk of gout is relatively greater in lower risk groups.
Table 3. Hazard ratios (95% confidence intervals) for risk of hypertension according to gout status:
The Singapore Chinese Health Study (1999–2010).
Cases/person-years Model 1 Model 2
Baseline (follow-up I) gout status
No 5265/124476 1.00 (ref) 1.00 (ref)
Yes 185/3521 1.28 (1.11–1.49) 1.18 (1.02–1.37)
Stratiﬁed by sexa
Men
No 2049/50003 1.00 (ref) 1.00 (ref)
Yes 120/2058 1.46 (1.21–1.75) 1.31 (1.09–1.58)
Women
No 3216/74474 1.00 (ref) 1.00 (ref)
Yes 65/1463 1.01 (0.78–1.29) 0.93 (0.72–1.19)
Stratiﬁed by BMI categorya
Normal weight
No 3422/90073 1.00 (ref) 1.00 (ref)
Yes 95/1857 1.40 (1.14–1.72) 1.34 (1.09–1.65)
Overweight/obesity
No 1843/34406 1.00 (ref) 1.00 (ref)
Yes 90/1664 1.01 (0.82–1.25) 1.01 (0.81–1.25)
Duration of gout
No gout 5265/124476 1.00 (ref) 1.00 (ref)
0.1–4.9 years 90/1767 1.24 (1.01–1.53) 1.14 (0.93–1.41)
5.0 years 95/1754 1.33 (1.09–1.63) 1.21 (0.99–1.49)
P for trendb 0.001 0.03
2-year lag analysisc
No 4922/85227 1.00 (ref) 1.00 (ref)
Yes 169/2391 1.26 (1.08–1.47) 1.16 (0.99–1.35)
Model 1: adjusted for age, sex, dialect, year of interview, and educational level.
Model 2: model 1 plus body mass index, physical activity, smoking status, alcohol use, and history of
diabetes at follow-up I.
aThe P for interaction was 0.02 for sex, and 0.04 for BMI category (<24 and 24 kg/m2).
bP for trend was calculated by treating the categorical variable of duration of gout as a continuous variable.
c359 participants were excluded from the analysis.
doi:10.1371/journal.pone.0141749.t003
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To the best of our knowledge, our study is the first to report an association between self-
reported gout and development of hypertension in a cohort of middle-aged and elderly Chi-
nese. A recent meta-analysis of 18 prospective cohort studies reported that hyperuricemia (by
different definitions) was associated with a 41% increased risk of developing hypertension, and
each 1 mg/dL increase in uric acid level was associated with a 13% increase in risk [17]. Positive
association between uric acid levels and new-onset hypertension has been reported in Chinese
populations as well [32–35]. Our study adds further evidence that gout is associated with an
increased risk of developing hypertension. We also found significant interaction with sex, and
the association was evident in men but not in women. A cross-sectional study in middle-aged
Chinese reported that hyperuricemia was associated with higher odds of hypertension in men
compared that in women [36]. However, in the above mentioned meta-analysis, stronger asso-
ciation between hyperuricemia and incident hypertension was found in women instead (RR
1.76; 95% CI 1.46–2.05) compared to men (RR 1.38; 95% CI 1.20–1.57). Thus, the sex differ-
ence in the association is still inconsistent and deserves further investigation. We also found
stronger association in normal weight participants compared to their overweight counterparts,
which is consistent with a cohort study in male Japanese workers that serum uric acid was asso-
ciated with an increased risk of hypertension in leaner men [37].
There are several plausible explanations for the bidirectional association between hyperten-
sion and gout. First, hypertension can cause glomerular arteriolar damage and glomerulo-
sclerosis, which then lead to renal insufficiency and decreased renal excretion of urate [38].
The reduced renal blood flow with increased renal and systemic vascular resistance may also
contribute to hyperuricemia in hypertensive patients [39]. Furthermore, certain antihyperten-
sive drugs also influence the levels of serum uric acid and thus may contribute to the develop-
ment of gout. For example, diuretics, β blockers, angiotensin converting enzyme inhibitors,
and non-losartan angiotensin II receptor blockers were associated with an increased risk of
gout in hypertensive patients [40]. On the other hand, uric acid has a pathogenic role in hyper-
tension [41–43], mediated by several mechanisms such as vascular smooth muscle cell prolifer-
ation [44], increased C-reactive protein expression [45], endothelial dysfunction and decreased
nitric oxide production [46], and local activation of the renin-angiotensin system [47]. Experi-
mental studies have further shown that a rise in serum uric acid caused by inhibition of uricase
in the rats results in systemic hypertension that is preventable by lowering uric acid with either
xanthineoxidase inhibitors or uricosuric agents [48–50]. Consistent with the experimental evi-
dence, elevated childhood serum uric acid levels were found to directly correlate with blood
pressures in untreated children [51], and also with higher blood pressure levels that persisted
into adulthood [52]. Meanwhile, lowering uric acid with allopurinol directly decreased blood
pressures in hyperuricaemic adolescents with newly diagnosed hypertension [53], as well as in
adults [54,55], suggesting a causal relation between serum uric acid levels and hypertension.
Finally, this substantial burden of comorbidity of hypertension and gout may possibly stems
from common pathogenesis of the two conditions, such as unhealthy lifestyles, obesity, insulin
resistance, and inflammation.
The strength of this study is the large sample with sufficient number of incident gout/hyper-
tension cases identified from a population-based prospective cohort with a relatively long-term
follow-up. We have tried to control multiple potential risk factors for gout or hypertension
in our analysis. In addition, participants with prevalent history of cancers, coronary heart dis-
ease, and stroke were excluded from the analysis since they could be associated with gout or
hypertension.
Our study has some limitations. A potential limitation is that both hypertension and gout
were self-reported, and we did not collect detailed information on the treatment of the dis-
eases. Previous studies have suggested that anti-hypertensive drugs may contribute to the
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development of gout, and diuretics, β blockers, and angiotensin converting enzyme inhibitors
were associated with an increased risk of gout [40], and those medications have been com-
monly prescribed to hypertensive patients in Singapore [56]. Therefore, part of the increased
risk of developing gout in hypertensive patients might be explained by the effects of drugs.
However, some studies have suggested that the association was independent of diuretic use
[27,30]. Shortly after Follow-up I, a sub-cohort of the participants (20,013 out of 31,137 par-
ticipants in analysis 1) responded to supplemental questionnaires with a question about anti-
hypertensive drug usage (without information on types of drugs). Among the participants
reported to have hypertension, 74.5% of them used medications to control blood pressures;
while among those without self-reported hypertension, only 4% used anti-hypertensive drugs
(data not shown). This provided a complimentary information about the validity of hyper-
tension in this study, but this was not optimal because the information on medication use
was not complete for all participants at all follow-up visits, and was self-reported itself with
limited capacity as a gold standard. We did not have information on the serum uric acid lev-
els or renal function, and thus could not test whether the association was due to the relatively
higher blood levels of uric acid or higher prevalence of renal impairment in hypertensive
patients. A previous study found that the association was substantially attenuated with
adjustment for serum urate levels [30]. Furthermore, validation using drug prescription data
and medical records for gout and hypertension was not feasible in our study. As for gout,
although we had trained our interviewers to further enquire about hyperuricemia in order
to increase the accuracy of self-reported gout, misclassification is possible. As with large pop-
ulation-based studies, it is not feasible to require the presence of intra-articular urate crystals
or tophus as the gold standard for diagnosis of gout. Although a study in US showed that
self-report of physician-diagnosed gout had moderate to good reliability and sensitivity, and
the authors have suggested that self-report of physician-diagnosed gout is appropriate for
epidemiologic studies [57], the validity of self-reported gout in our study is unknown. Fur-
thermore, the methodology of confirming gout cases by affirmative answer to the question
“Have you been told by a doctor to have gout?” has been commonly used in other popula-
tion-based large cohort studies [11,58]. Surveillance bias due to disease diagnosis is also a
possible explanation for our findings, since people with hypertension or gout may be more
likely to see the doctors and get their blood pressures or serum uric acid levels measured. We
have applied the 2-year lag analysis and the results remained unchanged; however, we do not
have information on frequency of general practitioner visits and could not fully account for
this bias.
In conclusion, our prospective cohort study provides evidence of a bidirectional association
between hypertension and gout, and the association may be modified by sex and obesity status.
Our study has been limited by the self-reported measures of hypertension and gout, thus, more
studies with validated assessments of both hypertension and gout are warranted. Future studies
are also needed to confirm our findings in different populations and to investigate the potential
mechanisms. If they can be replicated, our findings have significant public health and clinical
importance, because both conditions are common in Asia and globally, and that they are major
risk factors for cardiovascular disease and premature death.
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